+ Watch AVNR
on My Watchlist
A pharmaceutical company focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.
avnr is a takeover target for big business, has approved drug, little or no debt and enough money for its production and distribution, I believe that large company that already has spoken waiting for the Q4 11/30/2010 to offer for the shares, the next month I see some of these big companies could get started talking to avnr to buy next year
December 1, 2010 11:09 AM EST Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (NASDAQ: AVNR), PT $10. Canaccord analyst says, "We think AVNR will drive strong PBA awareness campaigns and continue strong clinician and patient outreach. We predict strong launch in February 2011. We think 923 will see good uptake starting H2/11. Our $10 target is based on a sum-of-the-parts analysis."
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions